However, PPARα was downregulated in patients with NASH compared to patients with steatosis and healthy controls [75, 86], and the expression of PPARα decreased with increasing NAFLD activity score and fibrosis stage [86]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.